Siponimod (Mayzent) is a sphingosine 1-phosphate (S1P) receptor modulator used for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. As a prescription medication, extra caution is required regarding its purchasing channels, medication safety, and authenticity verification.
How to Purchase Siponimod (Mayzent)
Overseas Purchase
Patients may choose to consult and purchase siponimod at hospital pharmacies or legitimate drugstores in countries or regions where the medication has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase Through Medical Service Institutions
Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and can offer professional consultation and guidance.
Precautions for Purchasing Siponimod (Mayzent)
Prescription and Medication Supervision
The standard dose of siponimod is 2mg taken orally once daily for patients with CYP2C9*1/*1, *1/*2, or *2/2 genotypes. For patients with CYP2C91/*3 or *2/*3 genotypes, the recommended dose is 1mg taken orally once daily.
Tablets must be swallowed whole and should not be split, crushed, or chewed.
Dose titration (gradually increasing the dose over 4-5 days) is required at the initial stage of treatment.
Medication for Special Populations
Patients with heart disease: Patients with a history of bradycardia, AV block, or heart failure need monitoring during the first dose administration.
Patients with hepatic impairment: Regular monitoring of liver function is required.
Pregnant and lactating women: Siponimod has embryo-fetal toxicity. Women of childbearing age must use effective contraceptive measures until 10 days after discontinuing the medication.
Patients at risk of infection: Before treatment, testing for varicella-zoster virus antibodies is required. Patients with negative results should receive vaccination.
Management of Drug Interactions
Concomitant use with strong CYP2C9 inhibitors (e.g., fluconazole) or inducers should be avoided.
Caution is needed when used together with drugs that slow heart rate (e.g., beta-blockers).
Live vaccines should be avoided during treatment and within 4 weeks after discontinuing the medication.
Methods for Verifying the Authenticity of Siponimod (Mayzent)
Packaging Feature Verification
0.25mg tablets: Light red, round, biconvex film-coated tablets, engraved with "T" on one side.
1mg tablets: Purple-white, round, biconvex film-coated tablets, engraved with "L" on one side.
2mg tablets: Light yellow, round, biconvex film-coated tablets, engraved with "II" on one side.
Drug Information Verification
Import drug registration certificate number.
Production batch number and expiration date.
Manufacturer information (Novartis Pharmaceuticals Corporation).
